tyrosinamide has been researched along with kanamycin a in 1 studies
| Studies (tyrosinamide) | Trials (tyrosinamide) | Recent Studies (post-2010) (tyrosinamide) | Studies (kanamycin a) | Trials (kanamycin a) | Recent Studies (post-2010) (kanamycin a) |
|---|---|---|---|---|---|
| 40 | 0 | 13 | 7,169 | 187 | 946 |
| Protein | Taxonomy | tyrosinamide (IC50) | kanamycin a (IC50) |
|---|---|---|---|
| 3-oxoacyl-[acyl-carrier-protein] synthase 3 | Escherichia coli K-12 | 6.8 | |
| Gap junction beta-2 protein | Homo sapiens (human) | 9.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, H; Schacht, J; Sha, SH | 1 |
1 other study(ies) available for tyrosinamide and kanamycin a
| Article | Year |
|---|---|
NF-kappaB pathway protects cochlear hair cells from aminoglycoside-induced ototoxicity.
Topics: Aldehydes; Animals; Anti-Bacterial Agents; Auditory Threshold; Benzimidazoles; Blotting, Western; Calcium-Binding Proteins; Cell Cycle Proteins; Cell Death; Cell Fractionation; Cochlea; Cyclooxygenase Inhibitors; DNA Replication Timing; Drosophila Proteins; Drug Administration Schedule; Drug Interactions; Electrophoretic Mobility Shift Assay; Enzyme Activation; Hair Cells, Auditory; Hydroxybenzoates; Immunohistochemistry; Immunoprecipitation; Iron Chelating Agents; Kanamycin; Male; Membrane Glycoproteins; Mice; Mice, Inbred CBA; Molecular Chaperones; Nerve Tissue Proteins; NF-kappa B; Phosphorylation; Protective Agents; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Salicylates; Signal Transduction; Synaptotagmin I; Synaptotagmins; Time Factors; Tyrosine | 2005 |